Ralf Oheim

Ralf Oheim

Auto-generated profile, based on publicly available information

Ralf Oheim

Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Bone
Verified
Journal Article
Open access
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
GCGavin P.R. Clunie
Gavin P.R. Clunie
PHPascal Houillier
Pascal Houillier
SBSuzanne M. Jan de Beur
Suzanne M. Jan de Beur
Salvatore MinisolaSalvatore Minisola
Salvatore Minisola
LSLothar Seefried
Lothar Seefried
Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare acquired paraneoplastic disease that is challenging to diagnose and treat. TIO is characterized by hypophosphatemia resulting from excess levels of tumor-secreted fibroblast growth factor 23 (FGF23), one of the key physiological regulators of phosphate metabolism. Elevated FGF23 results in renal phosphate wasting and compromised vitamin D activation, ultimately resulting in osteomalacia. Patients typically present with progressive and non-specific symptoms, including bone pain, multiple pathological fractures, and progressive muscle weakness. Diagnosis is often delayed or missed due to the non-specific nature of complaints and lack of disease awareness. Additionally, the disease-causing tumors are often difficult to detect and localize because they are often small, lack localizing symptoms and signs, and dwell in widely variable anatomical locations. One of the current unmet needs in TIO that causes a delay in diagnosis is the measurement of fasting serum phosphate, which should be an inherent diagnostic component when assessing otherwise unexplained osteomalacia, fractures, and weakness. In cases of hypophosphatemia with inappropriate (sustained) phosphaturia and inappropriately normal or frankly low 1,25-dihydroxy vitamin D, differentiation of the potential causes of renal phosphate wasting should include measurement of FGF23, and TIO should be considered. Patients experience severe disability without treatment but complete excision of the tumor is typically curative and results in a dramatic reversal of symptoms. Two additional key current unmet needs in optimizing TIO management are: (1) the considerable delay in diagnosis and consequent delay between the onset of symptoms and surgical resection; and (2) alternative management. These may be addressed by raising awareness of TIO, and taking into consideration the accessibility and variability of different healthcare infrastructures. By recognizing the challenges associated with the diagnosis and treatment of TIO and by applying a stepwise approach with clear clinical practice guidelines, patient care and outcomes will be improved in the future.

29 October 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
JSJulian Stürznickel
Julian Stürznickel
TRTim Rolvien
Tim Rolvien
ADAlena Delsmann
Alena Delsmann
SBSebastian Butscheidt
Sebastian Butscheidt
FBFlorian Barvencik
Florian Barvencik
RORalf Oheim
Ralf Oheim
Reduced bone mineral density (BMD, i.e., Z‐score ≤‐2.0) occurring at a young age (i.e., premenopausal women, men <50 years) in the absence of secondary osteoporosis is considered early‐onset osteoporosis (EOOP). Mutations affecting the WNT signaling pathway are of special interest due to their key role in bone mass regulation. Here, we analyzed the effects of relevant LRP5 and LRP6 variants on the clinical phenotype, bone turnover, BMD and bone microarchitecture. After exclusion of secondary osteoporosis, EOOP patients (n=372) were genotyped by gene panel sequencing, and segregation analysis of variants in LRP5/LRP6 was performed. The clinical assessment comprised the evaluation of bone turnover parameters, BMD by dual‐energy X‐ray absorptiometry, and microarchitecture via high‐resolution peripheral quantitative computed tomography (HR‐pQCT). In 50 individuals (31 EOOP index patients, 19 family members), relevant variants affecting LRP5 or LRP6 were detected (42 LRP5 and 8 LRP6 variants), including 10 novel variants. Seventeen variants were classified as disease causing, 14 were variants of unknown significance, and 19 were BMD‐associated SNPs. One patient harbored compound heterozygous LRP5 mutations causing osteoporosis‐pseudoglioma syndrome. Fractures were reported in 37/50 individuals, comprising vertebral (18/50) and peripheral (29/50) fractures. Low bone formation was revealed in all individuals. A Z‐score ≤‐2.0 was detected in 31/50 individuals, and values at the spine were significantly lower than those at the hip (‐2.1 ± 1.3 vs. ‐1.6 ± 0.8; p=0.003). HR‐pQCT analysis (n=34) showed impaired microarchitecture in trabecular and cortical compartments. Significant differences regarding the clinical phenotype were detectable between index patients and family members but not between different variant classes. Relevant variants in LRP5 and LRP6 contribute to EOOP in a substantial number of individuals, leading to a high number of fractures, low bone formation, reduced Z‐scores, and impaired microarchitecture. This detailed skeletal characterization improves the interpretation of known and novel LRP5 and LRP6 variants.

14 May 2024 in JBMR Plus
Verified
Journal Article
Open access
PDF file
FBFelix N von Brackel
Felix N von Brackel
RORalf Oheim
Ralf Oheim
Iron is a vital trace element and exerts opposing effects on bone in both iron overload and iron deficiency situations. Remarkably, iron supplementation through intravenous infusion in patients with iron deficiency can also have detrimental effects on bone in special cases. The diverse mechanisms underlying these effects and their manifestations contribute to the complexity of this relationship. Iron overload impacts both bone resorption and formation, accelerating bone resorption while reducing bone formation. These effects primarily result from the direct action of reactive oxygen species (ROS), which influence the proliferation, differentiation, and activity of both osteoclasts and osteoblasts differently. This imbalance favors osteoclasts and inhibits the osteoblasts. Simultaneously, multiple pathways, including bone morphogenic proteins, RANK ligand, and others, contribute to these actions, leading to a reduction in bone mass and an increased susceptibility to fractures. In contrast, iron deficiency induces low bone turnover due to energy and co-factor deficiency, both of which require iron. Anemia increases the risk of fractures in both men and women. This effect occurs at various levels, reducing muscular performance and, on the bone-specific level, decreasing bone mineral density. Crucially, anemia increases the synthesis of the phosphaturic hormone iFGF23, which is subsequently inactivated by cleavage under physiological conditions. Thus, iFGF23 levels and phosphate excretion are not increased. However, in specific cases where anemia has to be managed with intravenous iron treatment, constituents—particularly maltoses—of the iron infusion suppress the cleavage of iFGF23. As a result, patients can experience severe phosphate wasting and, consequently, hypophosphatemic osteomalacia. This condition is often overlooked in clinical practice and is often caused by ferric carboxymaltose. Ending iron infusions or changing the agent, along with phosphate and vitamin D supplementation, can be effective in addressing this issue.

29 March 2018 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
SBS. Butscheidt
S. Butscheidt
ADA. Delsmann
A. Delsmann
TRT. Rolvien
T. Rolvien
FBF. Barvencik
F. Barvencik
MAM. Al-Bughaili
M. Al-Bughaili
ROR. Oheim
R. Oheim

1 June 2021 in Bone
Verified
Journal Article
Open access
SBSebastian Butscheidt
Sebastian Butscheidt
ETElena Tsourdi
Elena Tsourdi
TRTim Rolvien
Tim Rolvien
ADAlena Delsmann
Alena Delsmann
JSJulian Stürznickel
Julian Stürznickel
RORalf Oheim
Ralf Oheim
Pregnancy and lactation-associated osteoporosis (PLO) is a rare skeletal disorder characterized by early-onset osteoporosis typically manifestating with vertebral compression fractures or transient osteoporosis of the hip. We hypothesized that genetic variants may play a role in the development of PLO. This study aimed to analyze the presence of genetic variants and a potential association with the clinical presentation in PLO. 42 women with PLO were included from 2013 to 2019 in a multicenter study in Germany. All cases underwent comprehensive genetic analysis based on a custom-designed gene panel including genes relevant for skeletal disorders. The skeletal status was assessed using dual-energy X-ray absorptiometry (DXA). Subgroups were further analyzed by serum bone turnover markers (n = 31) and high-resolution peripheral computed tomography (HR-pQCT; n = 23). We detected relevant genetic variants in 21 women (50%), with LRP5, WNT1 and COL1A1/A2 being the most commonly involved genes. The mean number of vertebral compression fractures was 3.3 ± 3.4 per case with a significantly higher occurrence in the subgroup with genetic variants (4.8 ± 3.7 vs. 1.8 ± 2.3, p = 0.02). Among the total cohort, DXA Z-scores were significantly lower at the lumbar spine compared to the femoral neck (p = 0.002). HR-pQCT revealed a pronounced reduction of trabecular and cortical thickness, while trabecular number was within the reference range. Eighteen women (43%) received a bone-specific therapy (primarily teriparatide). Overall, a steep increase in bone mass (+37.7%) was observed after 3 years. In conclusion, pregnancy and lactation represent skeletal risk factors, which may unmask hereditary bone disorders leading to PLO. These cases were affected more severely. Nevertheless, a timely diagnosis and adequate treatment can ensure a substantial recovery potential even without specific therapy. Patients with genetically induced low bone turnover (e.g.; LRP5, WNT1) may especially benefit from osteo-anabolic medication.

1 January 2016 in Injury
Verified
Journal Article
Closed access
RORalf Oheim
Ralf Oheim
TSThorsten Schinke
Thorsten Schinke
MAMichael Amling
Michael Amling
PPPia Pogoda
Pia Pogoda